Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alexion Pharma IncfiledCriticalAlexion Pharma Inc
Priority claimed from PCT/US1995/005688external-prioritypatent/WO1995029697A1/en
Publication of MX9605330ApublicationCriticalpatent/MX9605330A/en
The use of anti-C5 antibodies, e.g., monoclonal antibodies, to treat glomerulonephritis (GN) is disclosed. The administration of such antibodies at low dosage levels has been found to significantly reduce glomerular inflammation/enlargement and other pathologic conditions associated with GN. Also disclosed are novel anti-C5 antibodies and anti-C5 antibody-encoding nucleic acid molecules. These antibodies are useful in the treatment of GN and other inflammatory conditions involving pathologic activation of the complement system.
MX9605330A1995-05-011995-05-01Methods and compositions for the treatment of glomerulonephritis and other inflammatory diseases.
MX9605330A
(en)
Methods of thrombus forming inhibition methods of tretment of thrombotic states, pharmaceutical compositions and kit for treatment of thrombotic states